Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

AGA releases BRCA risk guidance

Key clinical point: BRCA carrier status alone should not influence screening recommendations for colorectal cancer or pancreatic ductal adenocarcinoma.

Major finding: Pancreatic ductal adenocarcinoma is generally recommended only for BRCA carriers only if they have a family history of the disease.

Study details: A clinical practice update for risk-based screening of colorectal and pancreatic cancer.

Disclosures: The investigators reported no conflicts of interest.


Kupfer SS et al. Gastroenterology. 2020 Apr 23. doi: 10.1053/j.gastro.2020.03.086.